Youshan Capital was established at the end of 2019 by professional institutional partners including major central and state-owned enterprises, funds of funds and privately owned listed companies. At the time of this profile, it managed RMB3.3 billion in private equity funds and RMB10 billion in local industrial funds of funds.
The firm focuses on growth companies in technology and biopharmaceuticals. It had invested in more than 20 businesses, including Zhongke Weizhi (中科微至), Heyu Biopharma (和誉生物), AsiaInfo Security (亚信安全), Han’s Robot (大族机器人), Tankeblue (天科合达) and Abogen Biosciences (艾博生物). Three portfolio companies had listed on the STAR Market or the Hong Kong Stock Exchange.
Its team comprised nearly 30 people across offices including Shenzhen, Beijing and Shanghai. The three founding partners have many years of experience in private equity, domestic and international M&A, investment banking and corporate management. Most investment staff have at least ten years of investment or related experience. The team combines insight into emerging technology, expert support and industry relationships, and supports portfolio companies with market development, talent recruitment, strategic planning and capital transactions.
The team’s previous investments also include Meituan/Dianping, 360, DJI, Goldwind, BGI, SonoScape, Tianjiang Pharmaceutical, Wens Foodstuff, Beingmate and China Construction Bank, with strong reported returns.
From the original English profile
The English-language profile included these additional details.
YouShan raised its first RMB3.3 billion China-focused private equity fund in 2019, backed by major state-owned enterprises, financial institutions and Shenzhen government funds. It also managed a RMB10 billion fund of funds for a local government on China’s eastern seaboard, and included advanced manufacturing among its investment priorities. The two versions also give different portfolio names: “Wayz Intelligent” in English and “Zhongke Weizhi” in Chinese.